GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting formulation of the antiretroviral cabotegravir, which is being investigated for the treatment and prevention of HIV. The safety and pharmacokinetic data from the study support the potential to double dosing intervals to four months or longer, which could significantly reduce the number of clinic visits for patients.
ViiV Healthcare is exploring both an intramuscular version and a subcutaneous injection of the drug in conjunction with Halozyme Therapeutics’s (NASDAQ: HALO) proprietary hyaluronidase enzyme (rHuPH20). This collaboration aims to enhance the drug’s distribution and absorption.
The company intends to develop cabotegravir in combination with other compounds to create a comprehensive, ultra-long-acting HIV treatment regimen, potentially transforming the landscape of HIV management.- Flcube.com
